An existing lateral flow-based RDT for measles IgM detection has been field-validated with high sensitivity and specificity compared to ELISA, and this test is being commercialized, along with commercial development of a rubella IgM RDT; these tests have the potential use by non-expert users as part of MR surveillance [21]. This evidence concerns the gene CD40LG and measles.